novo nordisk semaglutide clinical trials FLOW Trial (funded by Nordisk): showed 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease compared to placebo. Investigators Shares in Danish drugmaker Novo

Individual variation is high and depends on your baseline metabolism, starting weight, and genetic factors

We're your Nocatee-area medical weight loss specialists

Meet with your doctor via video to review health history and goals

Some people use tirzepatide short term to help reinforce long-term habits, while others benefit from continued metabolic support

The study suggests that tesofensine, particularly at a dose of 0.5 mg, has the potential to produce twice the weight loss compared to currently approved drugs for obesity

PlexusDx maps 14 distinct peptide-pathway mechanisms across 49 biomarkers and 150+ genetic insights specific to your body's weight regulation